Remidio, a leader in AI-driven ophthalmic solutions, has announced a strategic investment in Occuity, a UK-based innovator in non-contact optical screening devices. This collaboration aims to enhance non-invasive screening for systemic diseases, with a particular focus on early myopia detection, eye disease screening, and diabetes monitoring.

With myopia cases in India projected to rise sharply—affecting nearly 48% of urban children by 2050—the partnership will introduce the country’s first handheld, non-invasive axial length measurement device. This affordable alternative to traditional eye exams will enable early diagnosis, especially for children, addressing the shortage of eye care professionals. Additionally, a handheld, non-contact corneal thickness measurement device will be developed to aid glaucoma management and LASIK suitability assessments.

By leveraging Remidio’s AI-powered diagnostics and extensive distribution network, the partnership will also support the launch of Occuity Indigo, a revolutionary optical glucose meter. This device offers pain-free blood glucose monitoring through an eye scan, eliminating the need for finger-prick tests for over 100 million diabetic patients in India.

Both companies share a commitment to advancing accessible, preventive healthcare. Their collaboration will accelerate the adoption of non-invasive diagnostics, ensuring early disease detection and improved patient outcomes across India.